Acquired DNA mutations associated with in vivo hydroxyurea exposure
Tóm tắt
Hydroxyurea (HU) is an effective therapeutic agent for patients with myeloproliferative disorders (MPDs) or sickle cell disease (SCD). Short-term HU toxicities primarily include transient myelosuppression, but long-term HU risks have not been defined. The mutagenic and carcinogenic potential of HU is not established, although HU has been associated with an increased risk of leukemia in some patients with MPD. In this study, 2 assays were used to quantitate acquired somatic DNA mutations in peripheral blood mononuclear cells (PBMCs) after in vivo HU exposure. The HPRT assay measures hypoxanthine phosphoribosyl transferase (hprt) mutations, while the VDJ assay identifies “illegitimate” T-cell receptor Vγ-Jβ interlocus recombination events. PBMCs were analyzed from patients with MPD, adults and children with SCD, and normal controls. MPD patients with prolonged HU exposure had numbers of DNA mutations equivalent to patients with low HU exposure or controls. Similarly, adults with SCD had equivalent numbers of DNA mutations regardless of HU exposure. Children with SCD and 30-month HU exposure had equivalenthprt− mutations but significantly more VDJ mutations (1.82 ± 1.20 events per μg DNA) than children with 7-month HU exposure (1.58 ± 0.87 events) or no HU exposure (1.06 ± 0.45 events), P = .04 by analysis of variance. Taken together, these data suggest that the mutagenic and carcinogenic potential of in vivo HU therapy is low. Although increased numbers of illegitimate VDJ recombination events do not directly portend leukemia, young patients with SCD and HU exposure should be monitored serially for increases in DNA mutations.
Tài liệu tham khảo
Berk, 1986, Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols., Semin Hematol., 23, 132
Murphy, 1986, Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group., Semin Hematol., 23, 177
Albain, 1990, Cisplatin preceded by concurrent cytarabine and hydroxyurea: a pilot study based on an in vitro model., Cancer Chemother Pharmacol., 27, 33, 10.1007/BF00689273
Wadler, 1996, Phase I trial of high-dose infusional hydroxyurea, high-dose infusional 5-fluorouracil and recombinant interferon-alpha-2a in patients with advanced malignancies., Invest New Drugs, 13, 315, 10.1007/BF00873137
Krakoff, 1968, Inhibition of ribonucleoside diphosphate reductase by hydroxyurea., Cancer Res., 28, 1559
Moore, 1985, The inhibition of ribonucleoside diphosphate reductase by hydroxyurea, guanazole and pyrazoloimidazole (IMPY)., Pharmacol Ther., 27, 167, 10.1016/0163-7258(85)90068-3
Timson, 1975, Hydroxyurea., Mutat Res., 32, 115, 10.1016/0165-1110(75)90002-0
Griffith, 1964, Hydroxyurea (NSC-32065): results of a phase I study., Cancer Chemother Rep., 40, 33
Platt, 1984, Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia., J Clin Invest., 74, 652, 10.1172/JCI111464
Charache, 1992, Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia., Blood., 79, 2555, 10.1182/blood.V79.10.2555.2555
Rodgers, 1990, Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea., New Engl J Med., 322, 1037, 10.1056/NEJM199004123221504
Charache, 1995, Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia., New Engl J Med., 332, 1317, 10.1056/NEJM199505183322001
Kinney, 1999, Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial., Blood., 94, 1550
Gebhart, 1981, Sister chromatid exchange (SCE) and structural chromosome aberration in mutagenicity testing., Hum Genet., 58, 235, 10.1007/BF00294917
Oppenheimer, 1965, Induction of chromosome breaks in cultured normal human leucocytes by potassium arsenite, hydroxyurea and related compounds., Cancer Res., 25, 980
Murphy, 1964, Preliminary survey of hydroxyurea (NSC-32065) as a teratogen., Cancer Chemother Rep., 40, 1
Aliverti, 1980, Hydroxyurea as a reference standard in teratological screening., Arch Toxicol Suppl., 4, 239, 10.1007/978-3-642-67729-8_49
Ziegler-Skylakakis, 1985, Microsome- and hepatocyte-mediated mutagenicity of hydroxyurea and related aliphatic hydroxamic acids in V79 Chinese hamster cells., Mutat Res., 152, 225, 10.1016/0027-5107(85)90065-X
Sedlacek, 1986, Essential thrombocythemia and leukemic transformation., Medicine (Baltimore)., 65, 353, 10.1097/00005792-198611000-00001
Lofvenberg, 1990, Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease., Cancer Genet Cytogenet., 49, 57, 10.1016/0165-4608(90)90164-6
Holcombe, 1991, Chronic myelomonocytic leukemia transformation in polcythemia vera., Leukemia., 5, 606
Furgerson, 1996, Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea., Am J Hematol., 51, 137, 10.1002/(SICI)1096-8652(199602)51:2<137::AID-AJH7>3.0.CO;2-Z
Landaw, 1986, Acute leukemia in polycythemia vera., Semin Hematol., 23, 156
Weinfeld, 1994, Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications., Eur J Haematol., 52, 134, 10.1111/j.1600-0609.1994.tb01303.x
Najean, 1997, Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years., Blood., 90, 3370, 10.1182/blood.V90.9.3370
Najean, 1997, Treatment of polycythemia vera: use of 32P alone or with a maintenance therapy using hydroxyurea in 461 patients aged more than 65 years., Blood., 89, 2319, 10.1182/blood.V89.7.2319
Fruchtman, 1997, From efficacy to safety: a Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera., Semin Hematol., 34, 17
Sterkers, 1998, Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion., Blood., 91, 616, 10.1182/blood.V91.2.616
Triadou, 1994, Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease., Nouv Rev Fr Hematol., 36, 367
Steinberg, 1999, Risks and benefits of hydroxyurea (HU) in adult sickle cell anemia: effects at 6- to 7- years [abstract]., Blood., 94, 644a
Albertini, 1982, T-cell cloning to detect the mutant 6-thioguanine-resistant lymphocytes present in human peripheral blood., Proc Natl Acad Sci U S A., 79, 6617, 10.1073/pnas.79.21.6617
O'Neill, 1987, Refinement of a T-lymphocyte cloning assay to quantify the in vivo thioguanine-resistant mutant frequency in humans., Mutagenesis., 2, 87, 10.1093/mutage/2.2.87
Stern, 1989, Inversion of chromosome 7 in ataxia-telangiectasia is generated by a rearrangement between T-cell receptor β and T-cell receptor γ genes., Blood., 74, 2076, 10.1182/blood.V74.6.2076.2076
Lipkowitz, 1990, Hybrid T cell receptor genes formed by interlocus recombination in normal and ataxia-telangiectasia lymphocytes., J Exp Med., 172, 409, 10.1084/jem.172.2.409
Purow, 1999, Genetic instability and the etiology of PIG-A mutations in paroxysmal nocturnal hemoglobinuria., Blood Cells Mol Dis., 25, 79, 10.1006/bcmd.1999.0229
Ware, 1993, Phenotypic and clonal analysis of T lymphocytes in childhood immune thrombocytopenic purpura., Blood., 82, 2137, 10.1182/blood.V82.7.2137.2137
Lipkowitz, 1992, Interlocus V-J recombination measures genomic instability in agriculture workers at risk for lymphoid malignancies., Proc Natl Acad Sci U S A., 89, 5301, 10.1073/pnas.89.12.5301
Snyder, 1984, The role of deoxynucleoside triphosphate pools in the inhibition of DNA-excision repair and replication in human cells by hydroxyurea., Mutat Res., 131, 163
Li, 1987, Progressive formation of DNA lesions in cultured Ehrlich ascites tumor cells treated with hydroxyurea., Cancer Res., 47, 2755
Albertini, 1985, Somatic gene mutations in vivo as indicated by the 6-thioguanine-resistant T-lymphocytes in human blood., Mutat Res., 150, 411, 10.1016/0027-5107(85)90138-1
Langlois, 1986, Measurements of the frequency of human erythrocytes with gene expression loss phenotypes at the glycophorin A locus., Hum Genet., 74, 353, 10.1007/BF00280485
Kyoizumi, 1990, Spontaneous loss and alteration of antigen receptor expression in mature CD4+ T cells., J Exp Med., 171, 1981, 10.1084/jem.171.6.1981
Huttner, 1990, Increased frequency of 6-thioguanine-resistant lymphocytes in peripheral blood of workers employed in cyclophosphamide production., Mutat Res., 243, 101, 10.1016/0165-7992(90)90030-N
Hirota, 1994, Somatic mutations at T-cell antigen receptor and glycophorin A loci in pediatric leukemia patients following chemotherapy: comparison with HPRT locus mutation., Mutat Res., 315, 95, 10.1016/0921-8777(94)90010-8
Homans, 1995, Monitoring for chemotherapy genotoxicity in pediatric oncology patients utilizing HPRT., Blood., 86(suppl), 436a
Chen, 1996, Etoposide causes illegitimate V(D)J recombination in human lymphoid leukemic cells., Blood., 88, 2210, 10.1182/blood.V88.6.2210.bloodjournal8862210
Tates, 1991, Use of the clonal assay for the measurement of frequencies of HPRT mutants in T-lymphocytes from five control populations., Mutat Res., 253, 199, 10.1016/0165-1161(91)90133-S
Finette, 1994, Determination of hprt mutant frequencies in T-lymphocytes from a healthy pediatric population: statistical comparison between newborn, children and adult mutant frequencies, cloning efficiency and age., Mutat Res., 308, 223, 10.1016/0027-5107(94)90157-0
Poplack, 1989, Acute lymphoblastic leukemia., Principles and Practice of Pediatric Oncology., 323
Fuscoe, 1992, V(D)J recombinase-mediated deletion of the hprt gene in T-lymphocytes from adult humans., Mutat Res., 283, 13, 10.1016/0165-7992(92)90116-Y
Aplan, 1990, Disruption of the human SCL locus by “illegitimate” V-(D)-J recombinase activity., Science., 250, 1426, 10.1126/science.2255914